​Effective February 10, 2023, Aripiprazole (Abilify Maintena®), Aripiprazole (Aristada®), Olanzapine (Zyprexa Relprevv™), Paliperidone (Invega Sustenna®), Risperidone (Risperdal Consta®) have been added to the ADAP formulary.

The American Psychiatric Association guidelines recommend long-acting injectable antipsychotic medications as an option for patients with Schizophrenia who prefer a long-acting injectable and for patients who have had difficulty in adhering to oral daily medication. The benefits of long-acting injectable antipsychotic medications in these settings include decreased risk of mortality, reduced risk of hospitalization, better adherence, and improved privacy for these highly stigmatized illnesses. A significant number of people with HIV will experience new onset severe mental health illness requiring antipsychotic medication treatment (0.2% - 15%) and this risk increases with advanced HIV infection. Mental illness with psychotic symptoms can complicate adherence and linkage to effective HIV treatment.  The co-occurrence of HIV and psychosis together results in more morbidity and mortality than would be expected with either illness alone. The addition of these medications provides options to ensure that ADAP clients receive care consistent with current national guidelines to manage severe depression, schizophrenia, and schizoaffective disorder among people with HIV. 

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of Aripiprazole (Abilify Maintena®), Aripiprazole (Aristada®), Olanzapine (Zyprexa Relprevv™), Paliperidone (Invega Sustenna®), Risperidone (Risperdal Consta®).

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov ).

Thank you, 

Sharisse Kemp, MSW

ADAP Branch Chief

California Department of Public Health